Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Clin Pract ; 75(11): e14734, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34387911

ABSTRACT

AIM: There is a lack of an overview of the factors associated with postacute COVID-19 musculoskeletal symptoms. The aims of this study were as follows: 1- to evaluate the most frequent admission symptoms and the frequency of musculoskeletal symptoms in postacute COVID-19 patients; and 2- to determine the related factors with the postacute COVID-19 musculoskeletal symptoms. METHODS: A total of 280 postacute COVID-19 patients (183 females, 97 males) were enrolled and divided into two groups: 1- patients whose musculoskeletal symptoms initiated with or were aggravated by COVID-19 (n = 240); and 2- patients whose musculoskeletal symptoms did not change with COVID-19 (n = 40). The variables were demographic and treatment data, symptoms on admission, postacute COVID-19 symptoms, laboratory results (complete blood count, erythrocyte sedimentation rate, C-reactive protein, ferritin and d-dimer), chest computed tomography findings and symptoms during acute COVID-19. RESULTS: Most of the patients have fatigue (71.8%), spine pain (70.7%) and myalgia (60.7%). The most common pain region was the back (30.4%). The frequency of dyspnoea was 30%, cough 18.5% and chest pain 10.7%. Having any chronic disease (P = .031), the duration of hospital stay (P = .016), frequency of back pain during acute COVID-19 (P = .018), tomography findings and d-dimer (P = .035) levels were significantly higher, and lymphocyte (P = .024) levels were significantly lower in the patients whose symptoms began with or were aggravated by COVID-19. CONCLUSION: Back pain was the most frequent symptom on admission. The most common postacute COVID-19 musculoskeletal symptoms were fatigue, spine pain and myalgia. Lower lymphocyte and higher d-dimer levels, the presence of COVID-19 findings in tomography and back pain during acute COVID-19 infection, higher duration of hospital stay and having chronic diseases were related to post-COVID-19 musculoskeletal symptoms.


Subject(s)
COVID-19 , Chest Pain , Dyspnea , Female , Hospitalization , Humans , Male , SARS-CoV-2
2.
Biosci Rep ; 40(7)2020 07 31.
Article in English | MEDLINE | ID: mdl-32578848

ABSTRACT

The present study was aimed to investigate the relationship between NOD1/CARD4 and NOD2/CARD15 gene polymorphisms and osteoporosis in the Turkish population. The first time we thought that the functional polymorphisms in NOD1/CARD4 and NOD2/CARD15 genes might have triggered the development of osteoporosis. The objective of our study was to determine the relationship between NOD1/CARD4 and NOD2/CARD15 SNPs and osteoporosis. The NOD1/CARD4 (rs5743336) and NOD2/CARD15 (rs2066847) SNPs were analyzed by PCR restriction fragment length polymorphism (PCR-RFLP) in 94 healthy controls and 164 subjects with osteoporosis. PCR products were digested with restriction enzymes AvaI for NOD1/CARD4 and ApaI for NOD2/CARD15. We found that NOD1/CARD4 genotype distribution of AA, GA and GG were 15, 44 and 41% for patients and 17, 46 and 37% for controls, respectively. NOD2/CARD15 mutation was found only in three patients (1.8%) as heterozygote. The results did not show any statistical difference between NOD1/CARD4 and NOD2/CARD15 genotype distribution of patients and healthy groups (χ2 = 1.740, P=0.187; χ2 = 1.311, P=0.519). However, the most frequent AG genotype (46%) of NOD1/CARD4 was observed in healthy controls, GG genotype (44%) of NOD1/CARD4 was observed as the most frequent in osteoporotic patients. NOD2/CARD15 WT/WT genotype, the most frequent genotype, was observed in both groups. Statistical analysis revealed that NOD1/CARD4 and NOD2/CARD15 polymorphisms are not associated with osteoporosis. However, a definite judgement is difficult to be made due to restricted number of patients and small size of control group. Further research is sorely warranted in this direction.


Subject(s)
Genetic Predisposition to Disease , Nod1 Signaling Adaptor Protein/genetics , Nod2 Signaling Adaptor Protein/genetics , Osteoporosis/genetics , Absorptiometry, Photon , Adult , Aged , Bone Density/genetics , Bone Density/immunology , Case-Control Studies , Female , Healthy Volunteers , Humans , Immunity, Innate/genetics , Male , Middle Aged , Osteoporosis/diagnosis , Osteoporosis/epidemiology , Osteoporosis/immunology , Polymorphism, Restriction Fragment Length , Risk Factors , Turkey/epidemiology
3.
Iran Red Crescent Med J ; 18(10): e37912, 2016 Oct.
Article in English | MEDLINE | ID: mdl-28184327

ABSTRACT

BACKGROUND: Monosodium glutamate (MSG) is a widely-used flavor enhancer and stabilizer in ready-made or packaged foods. The excessive use of MSG has been shown to increase oxidative stress in different organ systems and causes glucose metabolism disorders, obesity, and coronary diseases. OBJECTIVES: In this study, the antioxidant activity of tannic acid was investigated experimentally with respect to its protective effects against overdosed MSG-induced oxidative stress in rats. The study took place in Turkey in August 2013. METHODS: Four groups (n = 7) of three- to four-month-old Sprague-Dawley female rats were used in this study. The first group was the control, who were administered saline. The second group received tannic acid (50 mg/kg, 3 days) intraperitoneally (i.p.). The third group received MSG (2 g/kg, 7 days) i.p., and the fourth group received both tannic acid (50 mg/kg, 3 days, pretreatment) and MSG (2 g/kg, 7 days) i.p. The animals were euthanized ten days later. Blood was collected for determining the hematological values and blood glucose levels. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were determined in the brain, liver, and kidney homogenates, and in the erythrocyte hemolysate. Histopathological examination of the brain, liver, and kidneys was conducted through hematoxylin-eosin staining. RESULTS: The data showed that the tannic acid treatment statistically decreased the MDA levels in the brain tissues of the group administered MSG and tannic acid (P < 0.001) when compared to the corresponding values of the control group. The SOD activities in the blood hemolysates of the MSG and tannic acid group increased when compared to the corresponding values for the MSG group (P < 0.01). Additionally, we found that pretreatment with tannic acid reduced blood glucose levels in comparison to the levels of the MSG group (P = 0.029). The results of our study show that tannic acid pretreatment in adult rats decreased blood glucose levels and oxidative stress. CONCLUSIONS: In the literature, it was observed that short-term MSG exposure does not cause significant histological changes in the kidneys, liver, or brain cortex. These findings should be re-evaluated in additional long-term studies.

4.
Turk J Haematol ; 30(2): 153-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-24385778

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the clinical significance of reticulocyte hemoglobin content (CHr) in the diagnosis of iron deficiency anemia (IDA) and to compare it with other conventional iron parameters. MATERIALS AND METHODS: A total of 32 female patients with IDA (serum hemoglobin <120 g/L and serum ferritin <20 ng/ mL) and 18 female patients with iron deficiency (serum hemoglobin > 120 g/L and serum ferritin <20 ng/mL) were enrolled. RESULTS: CHr was 24.95±3.92 pg in female patients with IDA and 29.93±2.96 pg in female patients with iron deficiency. CHr showed a significant positive correlation with hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, serum iron, and transferrin saturation and a significant negative correlation with transferrin and total iron-binding capacity. The cut-off value of CHr for detecting IDA was 29 pg. CONCLUSION: Our data demonstrate that CHr is a useful parameter that can be confidently used in the diagnosis of IDA, and a CHr cut-off value of 29 pg predicts IDA. CONFLICT OF INTEREST: None declared.

5.
Arch Gynecol Obstet ; 273(2): 98-103, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16001193

ABSTRACT

OBJECTIVE: The aim of this study was to determine the apoptotic index using three different apoptotic markers: terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL); M30 cytoDEATH antibody and fluorescein isothiocyanate (FTIC)-labeled annexin-V in the placenta and membranes from normal pregnancy and pregnancy complicated by premature rupture of membranes (PROM). STUDY DESIGN: Placentas from 16 pregnancies (22-40 weeks' gestation) and 13 pregnancies complicated by pPROM and tPROM were collected at delivery. Maternal and gestational age, mode of delivery, gravidity and parity, fetal birthweight, Apgar scores, presence of histologic chorioamnionitis, interval between membrane rupture and delivery were recorded among PPROM and tPROM cases. RESULTS: Only M30 cytoDEATH antibody (P=0.02) and TUNEL test (P=0.04) on fetal membranes gave statistically significantly higher levels in cases with premature rupture of membranes. The presence of histologic chorioamnionitis had no significant impact on apoptotic markers in PROM placentas. Preterm deliveries following the rupture of membranes had higher median AI values detected by M30M antibody, compared to those cases delivered without PROM (P=0.03). CONCLUSION: High apoptotic nuclei counts were found in fetal membranes of pPROM.


Subject(s)
Apoptosis , Fetal Membranes, Premature Rupture/pathology , Placenta/pathology , Premature Birth/pathology , Annexin A5 , Antibodies, Monoclonal , Caspase 3 , Caspases/metabolism , Chorioamnionitis/pathology , Female , Gestational Age , Humans , Immunohistochemistry/methods , In Situ Nick-End Labeling , Placenta/cytology , Pregnancy
6.
Arch Gynecol Obstet ; 273(2): 86-9, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16001199

ABSTRACT

OBJECTIVE: To assess possible factors affecting the bone mineral density (BMD) in postmenopausal women. METHODS: A retrospective analysis of 267 cases with spontaneous menopause within 3 years of period was performed. None of the enrolled cases were taken any hormone replacement therapy and/or treatment for osteoporosis. BMD measurements were done in lumbal vertebral (L1-L4) and left femur (neck, intertrochanteric and ward triangle) via dual energy X-ray absorbtiometry (DEXA) method, yielding corresponding T-scores of above-mentioned areas. In addition, age at menarche, parity, menopausal age, duration of postmenopausal state, lactation, physical activity, cigarette smoking, dietary calcium intake, oral contraceptive use and body mass index (BMI) were determined. RESULTS: There were no relationships between BMD and age at menarche, parity, menopausal age, lactation, physical activity, smoking, dietary calcium intake and oral contraceptive use. Two associated factors with BMD were BMI and time since menopause. BMI was found to be positively and time since menopause was negatively correlated with BMD of both lumbal region and femur. CONCLUSIONS: BMD changes and its related factors should be kept in mind during postmenopausal years. Therefore, adequate peak bone mass and related life style measures should be achieved to confront osteoporosis-related symptoms and its consequences.


Subject(s)
Body Mass Index , Bone Density , Postmenopause/physiology , Female , Femur , Humans , Lumbar Vertebrae , Middle Aged , Osteoporosis, Postmenopausal/etiology , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...